Premium
Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man
Author(s) -
Moriearty Pamela L.,
Womack Cindy L.,
Dick Barrett W.,
Colliver Jerry A.,
Robbs Randall S.,
Becker Robert E. W.
Publication year - 1991
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830370415
Subject(s) - acetylcholinesterase , aché , enzyme , biology , enzyme assay , disease , endocrinology , medicine , platelet , cholinesterase , hematology , central nervous system , immunology , biochemistry
Acetylcholinesterase (AChE; EC 3.1.1.7) is present in both primitive and mature erythroid cells, and a role has been suggested for the enzyme in regulation of differentiation in the human erythron. AChE is also a major enzyme in the central nervous system; alteration of its activity has been proposed as a therapeutic strategy in Alzheimer disease. We recently treated 18 Alzheimer disease patients with metrifonate, a long‐acting AChE inhibitor, over periods up to 7 months, with resulting erythrocyte AChE inhibition as high as 82 per cent of baseline values. Despite chronic reduction of enzyme activity, no significant alterations were noted in erythrocyte, leukocyte or platelet characteristics or numbers that would suggest a deleterious effect of AChE inhibition on normal differentiation. Thus, any modification of developmental pathways appears to be compensated by other regulatory mechanisms in the intact organism.